A meta-analysis has revealed that participants in psilocybin trials experienced smaller reductions in depressive symptoms than those receiving selective serotonin reuptake inhibitors (SSRIs) or esketamine. This analysis, involving 17 randomized clinical trials with adults suffering from major depressive disorder (MDD) or treatment-resistant depression (TRD), highlights potential overestimations of psilocybin's antidepressant effects. Factors influencing these outcomes may include unblinding effects and varied patient expectations, suggesting that more rigorous trial designs are essential for future research.